MindBio Therapeutics is nearing the completion of its Phase IIa study investigating MB22001, a titratable form of lysergic acid diethylamide (LSD), in major depressive disorder patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,